0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Please Wait... Processing your request... Please Wait.

Not a subscriber yet?

Each month JAMA Oncology keeps you up-to-date with the most important advances in the field. Subscribe/Learn More

Current Highlights

Follow Us

Brief Report | August 25, 2016 FREE ONLINE FIRST

Financial Conflicts of Interest Among NCCN Guideline Authors

This study uses CMS' Open Payments Database data to describe the prevalence of financial conflicts of interest among authors of recent National Comprehensive Cancer Network guidelines.
Invited Commentary

Original Investigation | August 18, 2016 ONLINE FIRST

PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer

This meta-analysis summarizes the incidence of PD-1 inhibitor–related pneumonitis in patients with advanced cancer by tumor type and therapeutic regimen.

Original Investigation | August 11, 2016 ONLINE FIRST  audio icon

ESR1 Mutations in Metastatic Breast Cancer

This secondary analysis of a randomized clinical trial investigates the prevalence of ESR1 mutations in estrogen receptor–positive metastatic breast cancer and whether mutation is associated with inferior outcomes.
Invited Commentary

Featured article

August 11, 2016

Direct to Consumer Advertising in Oncology

These Viewpoints argue for and against the benefits of direct-to-consumer advertising of oncologic products and services.

Advantages of Direct-to-Consumer Advertising of Prescription Drugs
Disadvantages of Direct-to-Consumer Drug Advertising in Oncology

Review | August 4, 2016 ONLINE FIRST

Toward Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors

This narrative review discusses how genomic and transcriptomic tumor analysis can be used to select patients for therapy with immune checkpoint inhibitors.

Explore more articles:  Current Issue | Online First

Multimedia >

Author Interview

Author photo

Interview with Sarat Chandarlapaty, MD, PhD, author of Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial

audio player

RELATED ARTICLE:

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial

All Author Interviews >

Author Readings
Author photo

audio player

RELATED ARTICLE:


Latest Quiz

All Quizzes >

Waxing and Waning Pruritic Cutaneous Lesions Refractory to Antibiotics

A man in his 30s reported a 2-year history of waxing and waning pruritic papules involving his left popliteus, contralateral popliteus, groin, and penis with minimal response to antibiotics.

What is your diagnosis?

Image of JAMA forum logo

Physician Jobs